Published in:
01-10-2008 | Original Paper
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy
Authors:
Zhao-Hui Huang, Dong Hua, Li-Hua Li, Jing-De Zhu
Published in:
Journal of Cancer Research and Clinical Oncology
|
Issue 10/2008
Login to get access
Abstract
Objective
The polymorphism of p53 codon 72 (Arg72Pro) has been suggested to play an important role in many cancers and may influence the response to chemotherapy. Our aim was to investigate the association of p53 Arg72Pro polymorphism with the clinical outcome of gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.
Methods
The p53 codon 72 genotype was determined in blood samples from 110 Chinese patients with gastric cancer treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy, using polymerase chain reaction-ligation detection reaction (PCR–LDR) method.
Results
Kaplan–Meier survival analysis showed that gastric cancer patients with Pro/Pro genotype had shorter relapse-free survival (χ2 = 10.632, P = 0.005) and overall survival (χ2 = 7.104, P = 0.029) than patients with other genotypes. Cox multivariate analysis showed that Pro/Pro genotype was associated with statistically significant reduced relapse-free survival (adjusted OR = 3.049, 95% CI: 1.363–6.819, P = 0.007) and overall survival (adjusted OR = 2.581, 95% CI: 1.052–6.330, P = 0.038).
Conclusion
These results suggested that p53 codon 72 polymorphism appears to be an independent prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.